Treatment of Type II Gastric Carcinoid Tumors with Somatostatin Analogues

• Published in: The New England journal of medicine Vol. 343; no. 8; pp. 551 - 554
• Main Authors: Tomassetti, Paola, Migliori, Marina, Caletti, Gian Carlo, Fusaroli, Pietro, Corinaldesi, Roberto, Gullo, Lucio
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 24.08.2000
• Subjects: Adult; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Carcinoid Tumor - drug therapy; Carcinoid Tumor - etiology; Digestive system; Female; Gastrins - blood; Humans; Male; Medical research; Medical sciences; Middle Aged; Multiple Endocrine Neoplasia Type 1 - complications; Octreotide - therapeutic use; Peptides, Cyclic - therapeutic use; Pharmacology. Drug treatments; Somatostatin - analogs & derivatives; Somatostatin - therapeutic use; Stomach Neoplasms - drug therapy; Stomach Neoplasms - etiology; Tumors; Zollinger-Ellison Syndrome - complications; Human; Stomach; Peptide hormone; Laparoscopy; Carcinoid tumor; Case study; Chemotherapy; Treatment; Analog; Digestive diseases; Tumor; Endoscopy; Somatostatin; Gastric disease
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM200008243430805

Gastric carcinoid tumors are rare tumors that originate from gastric enterochromaffin-like cells in the oxyntic mucosa. 1 There are three types of gastric carcinoid tumors: type I is associated with chronic atrophic gastritis, type II develops in patients with combined multiple endocrine neoplasia type 1 and the Zollinger–Ellison syndrome, and type III is sporadic. 1 Although the pathogenesis of these tumors is not completely understood, hypergastrinemia has an important role in the development of types I and II. 2 The multiple endocrine neoplasia type 1 gene locus may be involved in type II gastric carcinoid tumors. 3 , 4 All three types are usually removed . . .